Details of the Drug Combination

General Information of Drug Combination (ID: DCMXYGQ)

Drug Combination Name
Rifabutin Azithromycin
Indication
Disease Entry Status REF
Mycobacterium Avium Complex Phase 1 [1]
Component Drugs Rifabutin   DM1YBHK Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifabutin
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Rifabutin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Rifabutin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [3]
Bronchitis CA20 Approved [4]
Chancroid N.A. Approved [3]
Mycoplasma pneumoniae pneumonia N.A. Approved [3]
Staphylococcus aureus infection N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Pneumonia caused by chlamydia N.A. Investigative [3]

References

1 ClinicalTrials.gov (NCT00598962) Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 Azithromycin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
5 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.